HC Wainwright & Co. Downgrades Capricor Therapeutics to Neutral

Benzinga · 2d ago
HC Wainwright & Co. analyst Joseph Pantginis downgrades Capricor Therapeutics (NASDAQ:CAPR) from Buy to Neutral.